# Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer

> **NCT00721916** · PHASE2 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 107 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)
- **DRUG:** mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)

## Key facts

- **NCT ID:** NCT00721916
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-03
- **Final completion:** 2012-05
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2012-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721916, "Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00721916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*